Vor Ev To Operating Cash Flow vs Income Quality Analysis

VOR Stock

USD 0.88 0.07 7.64%

Vor Biopharma financial indicator trend analysis is much more than just breaking down Vor Biopharma prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Vor Biopharma is a good investment. Please check the relationship between Vor Biopharma Ev To Operating Cash Flow and its Income Quality accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vor Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

To learn how to invest in Vor Stock, please use our How to Invest in Vor Biopharma guide.

Ev To Operating Cash Flow vs Income Quality

Ev To Operating Cash Flow vs Income Quality Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Vor Biopharma Ev To Operating Cash Flow account and Income Quality. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Vor Biopharma's Ev To Operating Cash Flow and Income Quality is 0.46. Overlapping area represents the amount of variation of Ev To Operating Cash Flow that can explain the historical movement of Income Quality in the same time period over historical financial statements of Vor Biopharma, assuming nothing else is changed. The correlation between historical values of Vor Biopharma's Ev To Operating Cash Flow and Income Quality is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ev To Operating Cash Flow of Vor Biopharma are associated (or correlated) with its Income Quality. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Income Quality has no effect on the direction of Ev To Operating Cash Flow i.e., Vor Biopharma's Ev To Operating Cash Flow and Income Quality go up and down completely randomly.

Correlation Coefficient

0.46

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Ev To Operating Cash Flow

A valuation metric comparing the company's enterprise value to its operating cash flow, indicating how many dollars of EV are generated for each dollar of operating cash flows.

Income Quality

An assessment of the sustainability of a company's earnings over time, considering factors like revenue source diversification and cost structure.

Most indicators from Vor Biopharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Vor Biopharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vor Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

To learn how to invest in Vor Stock, please use our How to Invest in Vor Biopharma guide.As of 03/04/2025, Selling General Administrative is likely to grow to about 38.3 M, while Issuance Of Capital Stock is likely to drop slightly above 103.9 M.

	2022	2023	2024	2025 (projected)
Reconciled Depreciation	2.5M	3.2M	3.7M	3.9M
Total Operating Expenses	93.4M	126.0M	144.9M	152.2M

Reconciled Depreciation Total Operating Expenses

Vor Biopharma fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Short Long Term Debt	Total Current Assets	Capital Stock	Net Working Capital	Short Term Debt
Total Assets		0.9	0.71	0.78	1.0	0.9	0.89	0.82	-0.49	-0.86	0.74	0.82	0.9	0.99	0.81	0.93	0.97	0.9	0.92	0.95	0.88	-0.34	0.99	-0.04	0.99	0.24
Short Long Term Debt Total	0.9		0.81	0.78	0.87	0.85	0.93	0.9	-0.18	-0.92	0.7	0.59	0.93	0.86	0.94	0.97	0.79	0.89	0.94	0.79	0.93	-0.43	0.85	0.08	0.85	0.06
Other Current Liab	0.71	0.81		0.8	0.68	0.84	0.91	0.71	-0.05	-0.94	0.57	0.5	0.92	0.66	0.85	0.82	0.6	0.89	0.83	0.59	0.92	-0.76	0.66	0.06	0.65	-0.01
Total Current Liabilities	0.78	0.78	0.8		0.74	0.78	0.83	0.56	-0.08	-0.85	0.45	0.47	0.83	0.73	0.75	0.89	0.67	0.81	0.93	0.72	0.83	-0.38	0.73	-0.06	0.71	0.33
Total Stockholder Equity	1.0	0.87	0.68	0.74		0.89	0.87	0.81	-0.54	-0.83	0.74	0.85	0.87	1.0	0.78	0.91	0.99	0.89	0.89	0.96	0.86	-0.33	1.0	-0.06	1.0	0.24
Net Tangible Assets	0.9	0.85	0.84	0.78	0.89		0.92	0.69	-0.25	-0.94	0.51	0.66	0.92	0.89	0.79	0.85	0.88	0.99	0.85	0.91	0.93	-0.62	0.89	-0.3	0.88	0.33
Property Plant And Equipment Net	0.89	0.93	0.91	0.83	0.87	0.92		0.79	-0.14	-0.97	0.69	0.61	1.0	0.86	0.86	0.95	0.8	0.96	0.94	0.79	1.0	-0.63	0.86	0.01	0.85	0.21
Current Deferred Revenue	0.82	0.9	0.71	0.56	0.81	0.69	0.79		-0.46	-0.76	0.85	0.73	0.8	0.8	0.93	0.84	0.75	0.74	0.79	0.66	0.78	-0.34	0.8	0.35	0.8	-0.31
Net Debt	-0.49	-0.18	-0.05	-0.08	-0.54	-0.25	-0.14	-0.46		0.1	-0.59	-0.86	-0.16	-0.56	-0.22	-0.24	-0.61	-0.2	-0.21	-0.45	-0.12	-0.15	-0.56	-0.22	-0.57	0.23
Retained Earnings	-0.86	-0.92	-0.94	-0.85	-0.83	-0.94	-0.97	-0.76	0.1		-0.57	-0.56	-0.97	-0.82	-0.89	-0.92	-0.77	-0.97	-0.92	-0.79	-0.97	0.6	-0.82	0.09	-0.81	-0.16
Accounts Payable	0.74	0.7	0.57	0.45	0.74	0.51	0.69	0.85	-0.59	-0.57		0.81	0.71	0.73	0.67	0.73	0.68	0.57	0.68	0.51	0.66	-0.28	0.73	0.61	0.73	-0.27
Cash	0.82	0.59	0.5	0.47	0.85	0.66	0.61	0.73	-0.86	-0.56	0.81		0.63	0.86	0.58	0.64	0.88	0.65	0.62	0.74	0.6	-0.24	0.86	0.18	0.87	-0.07
Non Current Assets Total	0.9	0.93	0.92	0.83	0.87	0.92	1.0	0.8	-0.16	-0.97	0.71	0.63		0.86	0.87	0.95	0.8	0.96	0.94	0.79	1.0	-0.64	0.86	0.03	0.85	0.18
Cash And Short Term Investments	0.99	0.86	0.66	0.73	1.0	0.89	0.86	0.8	-0.56	-0.82	0.73	0.86	0.86		0.76	0.89	0.99	0.88	0.88	0.96	0.85	-0.32	1.0	-0.06	1.0	0.25
Common Stock Shares Outstanding	0.81	0.94	0.85	0.75	0.78	0.79	0.86	0.93	-0.22	-0.89	0.67	0.58	0.87	0.76		0.9	0.7	0.83	0.88	0.67	0.86	-0.44	0.76	0.17	0.75	-0.19
Non Current Liabilities Total	0.93	0.97	0.82	0.89	0.91	0.85	0.95	0.84	-0.24	-0.92	0.73	0.64	0.95	0.89	0.9		0.83	0.89	0.99	0.82	0.94	-0.39	0.89	0.1	0.88	0.16
Other Current Assets	0.97	0.79	0.6	0.67	0.99	0.88	0.8	0.75	-0.61	-0.77	0.68	0.88	0.8	0.99	0.7	0.83		0.85	0.81	0.97	0.79	-0.29	0.99	-0.14	0.99	0.28
Other Stockholder Equity	0.9	0.89	0.89	0.81	0.89	0.99	0.96	0.74	-0.2	-0.97	0.57	0.65	0.96	0.88	0.83	0.89	0.85		0.89	0.87	0.97	-0.65	0.88	-0.21	0.87	0.28
Total Liab	0.92	0.94	0.83	0.93	0.89	0.85	0.94	0.79	-0.21	-0.92	0.68	0.62	0.94	0.88	0.88	0.99	0.81	0.89		0.81	0.93	-0.39	0.88	0.07	0.86	0.2
Net Invested Capital	0.95	0.79	0.59	0.72	0.96	0.91	0.79	0.66	-0.45	-0.79	0.51	0.74	0.79	0.96	0.67	0.82	0.97	0.87	0.81		0.79	-0.29	0.96	-0.34	0.96	0.44
Property Plant And Equipment Gross	0.88	0.93	0.92	0.83	0.86	0.93	1.0	0.78	-0.12	-0.97	0.66	0.6	1.0	0.85	0.86	0.94	0.79	0.97	0.93	0.79		-0.65	0.84	-0.01	0.83	0.21
Short Long Term Debt	-0.34	-0.43	-0.76	-0.38	-0.33	-0.62	-0.63	-0.34	-0.15	0.6	-0.28	-0.24	-0.64	-0.32	-0.44	-0.39	-0.29	-0.65	-0.39	-0.29	-0.65		-0.32	0.11	-0.31	-0.09
Total Current Assets	0.99	0.85	0.66	0.73	1.0	0.89	0.86	0.8	-0.56	-0.82	0.73	0.86	0.86	1.0	0.76	0.89	0.99	0.88	0.88	0.96	0.84	-0.32		-0.07	1.0	0.25
Capital Stock	-0.04	0.08	0.06	-0.06	-0.06	-0.3	0.01	0.35	-0.22	0.09	0.61	0.18	0.03	-0.06	0.17	0.1	-0.14	-0.21	0.07	-0.34	-0.01	0.11	-0.07		-0.07	-0.71
Net Working Capital	0.99	0.85	0.65	0.71	1.0	0.88	0.85	0.8	-0.57	-0.81	0.73	0.87	0.85	1.0	0.75	0.88	0.99	0.87	0.86	0.96	0.83	-0.31	1.0	-0.07		0.24
Short Term Debt	0.24	0.06	-0.01	0.33	0.24	0.33	0.21	-0.31	0.23	-0.16	-0.27	-0.07	0.18	0.25	-0.19	0.16	0.28	0.28	0.2	0.44	0.21	-0.09	0.25	-0.71	0.24

Click cells to compare fundamentals

Vor Biopharma Account Relationship Matchups

Vor Biopharma fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	75.9M	242.6M	299.4M	198.1M	227.8M	151.6M
Other Current Liab	6.1M	4.9M	4.8M	10.9M	12.6M	13.2M
Total Current Liabilities	10.2M	10.2M	13.1M	15.6M	17.9M	10.8M
Total Stockholder Equity	48.3M	216.3M	250.6M	150.7M	173.3M	122.2M
Net Tangible Assets	(17.4M)	(59.1M)	216.3M	250.6M	288.2M	302.6M
Property Plant And Equipment Net	21.8M	22.5M	57.1M	50.1M	57.6M	60.5M
Net Debt	(30.2M)	(101.8M)	(18.8M)	4.3M	3.9M	4.1M
Retained Earnings	(61.2M)	(130.1M)	(222.2M)	(340.1M)	(306.1M)	(290.8M)
Accounts Payable	2.4M	1.5M	1.8M	815K	937.3K	1.3M
Cash	48.5M	119.8M	57.7M	31.4M	36.1M	48.5M
Non Current Assets Total	26.8M	28.2M	62.4M	57.3M	65.9M	69.2M
Cash And Short Term Investments	48.5M	207.5M	230.2M	137.2M	157.8M	115.7M
Common Stock Shares Outstanding	37.1M	37.2M	39.6M	67.2M	77.3M	41.0M
Liabilities And Stockholders Equity	75.9M	242.6M	299.4M	198.1M	227.8M	151.6M
Non Current Liabilities Total	17.4M	16.2M	35.6M	31.8M	36.6M	18.7M
Other Current Assets	567K	6.9M	6.7M	3.6M	4.2M	3.3M
Other Stockholder Equity	2.2M	346.4M	473.6M	490.9M	564.5M	592.7M
Total Liab	27.6M	26.3M	48.8M	47.4M	54.5M	29.3M
Net Invested Capital	(59.1M)	216.3M	250.6M	150.7M	173.3M	98.8M
Property Plant And Equipment Gross	21.8M	24.6M	61.7M	58.2M	66.9M	70.3M
Total Current Assets	49.1M	214.4M	237.0M	140.8M	161.9M	119.1M
Capital Stock	25.1M	107.3M	4K	7K	6.3K	6.0K
Net Working Capital	38.9M	204.2M	223.8M	125.2M	144.0M	108.3M
Property Plant Equipment	728K	21.8M	6.9M	12.6M	14.5M	9.3M
Non Currrent Assets Other	3.4M	3.3M	2.9M	7.2M	8.3M	8.7M

Additional Tools for Vor Stock Analysis

When running Vor Biopharma's price analysis, check to measure Vor Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vor Biopharma is operating at the current time. Most of Vor Biopharma's value examination focuses on studying past and present price action to predict the probability of Vor Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vor Biopharma's price. Additionally, you may evaluate how the addition of Vor Biopharma to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Vor Ev To Operating Cash Flow vs Income Quality Analysis

Ev To Operating Cash Flow vs Income Quality

Ev To Operating Cash Flow vs Income Quality Correlation Analysis

Correlation Coefficient

Ev To Operating Cash Flow

Income Quality

Vor Biopharma fundamental ratios Correlations

Vor Biopharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Vor Biopharma fundamental ratios Accounts

Additional Tools for Vor Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Total Stockholder Equity
Net Working Capital	+ 1.0	Total Stockholder Equity
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net

Property Plant And Equipment Gross	- 0.97	Retained Earnings
Other Stockholder Equity	- 0.97	Retained Earnings
Non Current Assets Total	- 0.97	Retained Earnings
Retained Earnings	- 0.97	Property Plant And Equipment Net
Retained Earnings	- 0.94	Net Tangible Assets
Retained Earnings	- 0.94	Other Current Liab